12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iclusig ponatinib regulatory update

Ariad disclosed in its 2Q13 earnings that it submitted regulatory applications in Canada and Australia for Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >